Full Text View
Tabular View
No Study Results Posted
Related Studies
Phase I/II Safety Study of IPI-504 in Relapsed/Refractory Stage IIIb, or Stage IV Non-small Cell Lung Cancer (NSCLC)
This study has been completed.
Study NCT00431015   Information provided by Infinity Pharmaceuticals, Inc.

First Received on January 31, 2007.   Last Updated on December 6, 2012   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Lung Cancer
Additional conditions recognized in this trial
Carcinoma, Non-Small-Cell Lung
Lung Neoplasms
Pericardial Effusion
More general conditions related to this trial
Bronchial Neoplasms
Carcinoma, Bronchogenic
Cardiovascular Diseases
Heart Diseases
Lung Diseases
Neoplasms
Neoplasms by Site
Respiratory Tract Diseases
Respiratory Tract Neoplasms
Thoracic Neoplasms
Interventions listed in this trial
IPI-504
Sponsors listed in this trial
Infinity Pharmaceuticals, Inc.


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services